




## Supplementary Material



**Figure S1. The Cx30T5M mutation leads to a defective intercellular biochemical coupling but intact membrane targeting.** **A.** Immunocytochemical labeling for Cx30 (green) in transfected cultured cells shows proper Cx30T5M membrane targeting and GJ plaque formation, as compared to Cx30. Scale bar: 10  $\mu$ m. **B, C.** The Cx30T5M mutation causes an inhibition in gap junctional biochemical coupling compared to Cx30 transfected cells (Cx30:  $35.22 \pm 2.55$ ,  $n = 4$  cultures, Cx30T5M:  $2.44 \pm 0.36$ ,  $n = 4$  cultures), as revealed by biocytin diffusion (red) following scrape-loading. Scale bar: 100  $\mu$ m. Asterisks indicate statistical significance (\*\*\*)  $p < 0.001$ .



**Figure S2. Cx expression in cultured astrocytes.** **A.** Purity of astroglial cultures was assessed by immunocytochemistry for GFAP, MAP2, IB4 and DAPI. Sample images showing that the cultured cells are positive for the GFAP marker. Scale bars: 50  $\mu$ m. **B.** Immunoblots showing Cx30 and Cx43 protein levels in astrocytes transfected (+Cx30) or not (Ct) with the Cx30 plasmid. GAPDH was used as loading control. **C.** Quantitative analysis of the linear intensity profile of Cx30 and Cx43 ( $n = 5$  cultures) normalized to that of GAPDH. Asterisks indicate statistical significance (\*\* $p < 0.05$ ).



**Figure S3.** *In vivo* rescue of astroglial Cx30 expression in the hippocampus of  $Cx30^{-/-}$  mice. Cx30 protein was expressed *in vivo* specifically in astrocytes from  $Cx30^{-/-}$  mice by injection in the hippocampus at P15 of an AAV encoding Cx30 with a GFP reporter. GFAP, Cx30 and GFP labeling in hippocampal sections from  $Cx30^{-/-}$  mice (1-month-old) infected with AAVs at P15, showing local induction of Cx30 and GFP in astrocytes throughout the hippocampus. Scale bar: 250  $\mu\text{m}$ .